Dr. Chan on ExteNET Trial for HER2+ Breast Cancer

Arlene Chan, MD
Published: Sunday, Sep 27, 2015



Arlene Chan, MD, director, Mount Hospital at Perth, discusses the ExteNET trial, which looked at neratinib as extended adjuvant therapy in patients with early-stage HER2-positive breast cancer.

The phase III ExteNET trial randomized patients to 1 year of extended adjuvant treatment with oral agent neratinib at 240 mg daily versus placebo. Patients enrolled in the study had previously received trastuzumab-based adjuvant therapy. Disease-free survival was the primary endpoint.

Despite significant survival gains with trastuzumab, Chan says, up to 25% of patients will experience disease recurrence, suggesting the HER2-positive setting requires further interventions, such as neratinib.



Arlene Chan, MD, director, Mount Hospital at Perth, discusses the ExteNET trial, which looked at neratinib as extended adjuvant therapy in patients with early-stage HER2-positive breast cancer.

The phase III ExteNET trial randomized patients to 1 year of extended adjuvant treatment with oral agent neratinib at 240 mg daily versus placebo. Patients enrolled in the study had previously received trastuzumab-based adjuvant therapy. Disease-free survival was the primary endpoint.

Despite significant survival gains with trastuzumab, Chan says, up to 25% of patients will experience disease recurrence, suggesting the HER2-positive setting requires further interventions, such as neratinib.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x